M Azadi1, D M Bishai1, D W Dowdy2, L H Moulton3, S Cavalcante4, V Saraceni4, A G Pacheco5, S Cohn6, R E Chaisson2, B Durovni6, J E Golub2. 1. Department of Population Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. 2. Department of Epidemiology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. 3. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. 4. Municipal Health Secretariat, Rio de Janeiro, Brazil. 5. Scientific Computation Program, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. 6. Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract
OBJECTIVE: To estimate the incremental cost-effectiveness of tuberculosis (TB) screening and isoniazid preventive therapy (IPT) among human immunodeficiency virus (HIV) infected adults in Rio de Janeiro, Brazil. DESIGN: We used decision analysis, populated by data from a cluster-randomized trial, to project the costs (in 2010 USD) and effectiveness (in disability-adjusted life years [DALYs] averted) of training health care workers to implement the tuberculin skin test (TST), followed by IPT for TST-positive patients with no evidence of active TB. This intervention was compared to a baseline of usual care. We used time horizons of 1 year for the intervention and 20 years for disease outcomes, with all future DALYs and medical costs discounted at 3% per year. RESULTS: Providing this intervention to 100 people would avert 1.14 discounted DALYs (1.57 undiscounted DALYs). The median estimated incremental cost-effectiveness ratio was $2273 (IQR $1779-$3135) per DALY averted, less than Brazil's 2010 per capita gross domestic product (GDP) of $11,700. Results were most sensitive to the cost of providing the training. CONCLUSION:Training health care workers to screen HIV-infected adults withTST and provide IPT to those with latent tuberculous infection can be considered cost-effective relative to the Brazilian GDP per capita.
RCT Entities:
OBJECTIVE: To estimate the incremental cost-effectiveness of tuberculosis (TB) screening and isoniazid preventive therapy (IPT) among human immunodeficiency virus (HIV) infected adults in Rio de Janeiro, Brazil. DESIGN: We used decision analysis, populated by data from a cluster-randomized trial, to project the costs (in 2010 USD) and effectiveness (in disability-adjusted life years [DALYs] averted) of training health care workers to implement the tuberculin skin test (TST), followed by IPT for TST-positive patients with no evidence of active TB. This intervention was compared to a baseline of usual care. We used time horizons of 1 year for the intervention and 20 years for disease outcomes, with all future DALYs and medical costs discounted at 3% per year. RESULTS: Providing this intervention to 100 people would avert 1.14 discounted DALYs (1.57 undiscounted DALYs). The median estimated incremental cost-effectiveness ratio was $2273 (IQR $1779-$3135) per DALY averted, less than Brazil's 2010 per capita gross domestic product (GDP) of $11,700. Results were most sensitive to the cost of providing the training. CONCLUSION: Training health care workers to screen HIV-infected adults with TST and provide IPT to those with latent tuberculous infection can be considered cost-effective relative to the Brazilian GDP per capita.
Authors: Betina Durovni; Solange C Cavalcante; Valeria Saraceni; Vitoria Vellozo; Giselle Israel; Bonnie S King; Silvia Cohn; Anne Efron; Antonio G Pacheco; Lawrence H Moulton; Richard E Chaisson; Jonathan E Golub Journal: AIDS Date: 2010-11 Impact factor: 4.177
Authors: Taraz Samandari; Tefera B Agizew; Samba Nyirenda; Zegabriel Tedla; Thabisa Sibanda; Nong Shang; Barudi Mosimaneotsile; Oaitse I Motsamai; Lorna Bozeman; Margarett K Davis; Elizabeth A Talbot; Themba L Moeti; Howard J Moffat; Peter H Kilmarx; Kenneth G Castro; Charles D Wells Journal: Lancet Date: 2011-04-12 Impact factor: 79.321
Authors: David W Dowdy; Jonathan E Golub; Valeria Saraceni; Lawrence H Moulton; Solange C Cavalcante; Silvia Cohn; Antonio G Pacheco; Richard E Chaisson; Betina Durovni Journal: J Acquir Immune Defic Syndr Date: 2014-08-15 Impact factor: 3.731
Authors: Neil A Martinson; Grace L Barnes; Lawrence H Moulton; Reginah Msandiwa; Harry Hausler; Malathi Ram; James A McIntyre; Glenda E Gray; Richard E Chaisson Journal: N Engl J Med Date: 2011-07-07 Impact factor: 91.245
Authors: Alison D Grant; Salome Charalambous; Katherine L Fielding; John H Day; Elizabeth L Corbett; Richard E Chaisson; Kevin M De Cock; Richard J Hayes; Gavin J Churchyard Journal: JAMA Date: 2005-06-08 Impact factor: 56.272
Authors: D W Dowdy; G Israel; V Vellozo; V Saraceni; S Cohn; S Cavalcante; R E Chaisson; J E Golub; B Durovni Journal: Int J Tuberc Lung Dis Date: 2013-01-14 Impact factor: 2.373
Authors: Jonathan E Golub; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Bonnie S King; Anne Efron; Richard D Moore; Richard E Chaisson; Betina Durovni Journal: AIDS Date: 2007-07-11 Impact factor: 4.177
Authors: Gavin J Churchyard; Katherine L Fielding; James J Lewis; Leonie Coetzee; Elizabeth L Corbett; Peter Godfrey-Faussett; Richard J Hayes; Richard E Chaisson; Alison D Grant Journal: N Engl J Med Date: 2014-01-23 Impact factor: 91.245
Authors: J Ousley; K P Soe; N T T Kyaw; R Anicete; P E Mon; H Lwin; T Win; S Cristofani; A Telnov; M Fernandez; I Ciglenecki Journal: Public Health Action Date: 2018-03-21
Authors: I Pathmanathan; S Ahmedov; E Pevzner; G Anyalechi; S Modi; H Kirking; J S Cavanaugh Journal: Int J Tuberc Lung Dis Date: 2018-06-01 Impact factor: 2.373
Authors: Emily A Kendall; Andrew S Azman; Gary Maartens; Andrew Boulle; Robert J Wilkinson; David W Dowdy; Molebogeng X Rangaka Journal: AIDS Date: 2019-03-01 Impact factor: 4.177
Authors: Divya K Chandra; Anthony P Moll; Frederick L Altice; Elizabeth Didomizio; Laurie Andrews; Sheela V Shenoi Journal: Glob Public Health Date: 2021-03-02